Key Highlights
● Regeneron Pharmaceuticals closed at $790.74 on October 16, trading below the analyst target.
● The consensus 12-month price target is $863.93, implying about 9.3% upside.
● Analysts are split 19 Buy, 8 Hold, and 1 Sell on the stock.
● Targets range from $730 to $1,030 across 28 analysts.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) closed at $790.74 on October 16, 2026. The average analyst 12-month price target is $863.93, which is 9.3 % above that close, according to market data. Regeneron is a member of the S&P 500. The shares have drawn attention after a cluster of broker moves this month, including a UBS upgrade to Buy and a run of positive target changes.
What Is the Latest Analyst Price Target?
The consensus average target is $863.93, the median is $860, the high is $1030 and the low is $730, drawn from 28 analysts. Data date: October 16, 2026. The implied move from the latest price is 9.3 % upside, although targets are forecasts rather than guarantees.
What Are Analysts Saying?
The ratings split is 19 Buy, 8 Hold, 1 Sell, giving a consensus rating of Buy. Recent actions include UBS initiating or upgrading to Buy with a $978 target on October 14, 2026, Bank of America reiterating Buy with a $908 target and BMO Capital maintaining Buy with a $920 target on 12 October, while Wells Fargo (Hold, $750, 15 October) and Scotiabank (Hold, $770, 14 October) remained more cautious. Company news headlines noted a UBS upgrade from Neutral to Buy, a positive European CHMP recommendation for an alternative Libtayo dosing schedule, and Phase 3 results for Pasatru in fibrodysplasia ossificans progressiva.
What Could Help the Stock Reach the Price Target?
Supportive factors could include progress across the company's late-stage pipeline, regulatory milestones for products such as Libtayo, and an expanded collaboration with Sanofi noted in filings dated October 1, 2026. Upgrades from large brokers can also broaden the investor base if they are followed by supportive earnings. If the consensus proves accurate, the shares could move towards the average target over the next twelve months, but this depends on earnings delivery and market conditions.
What Could Prevent the Stock Reaching the Target?
The low target of $730 sits below the current price, and several brokers, including Wells Fargo and Scotiabank, hold neutral ratings. Pharmaceutical shares can be sensitive to clinical-trial outcomes, pricing and policy developments, and competition for key franchises, any of which could weigh on results. Analyst targets are revised frequently and can be wrong, and the figures above may differ between data providers.
What Should Investors Watch Next?
The next earnings report is scheduled for October 30, 2026. Investors may also watch further pipeline readouts, regulatory decisions in Europe and the US, and any revisions to broker targets after the results.
Closing In on Target
The consensus target of $863.93 for Regeneron suggests 9.3 % upside from the $790.74 close on October 16, 2026, based on 28 analysts.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...